

Kimia T Maleki

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/182896/kimia-t-maleki-publications-by-year.pdf>
Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

19 papers	1,256 citations	11 h-index	21 g-index
21 ext. papers	1,871 ext. citations	13.2 avg, IF	3.55 L-index

#	Paper	IF	Citations
19	SARS-CoV-2 Nsp13 encodes for an HLA-E-stabilizing peptide that abrogates inhibition of NKG2A-expressing NK cells.. <i>Cell Reports</i> , 2022 , 110503	10.6	2
18	MAIT cell activation is associated with disease severity markers in acute hantavirus infection. <i>Cell Reports Medicine</i> , 2021 , 2, 100220	18	3
17	Evaluation of 11 SARS-CoV-2 antibody tests by using samples from patients with defined IgG antibody titers. <i>Scientific Reports</i> , 2021 , 11, 7614	4.9	11
16	Shedding of infectious SARS-CoV-2 by hospitalized COVID-19 patients in relation to serum antibody responses. <i>BMC Infectious Diseases</i> , 2021 , 21, 494	4	4
15	SARS-CoV-2-specific humoral and cellular immunity persists through 9 months irrespective of COVID-19 severity at hospitalisation. <i>Clinical and Translational Immunology</i> , 2021 , 10, e1306	6.8	16
14	A heterozygous germline CD100 mutation in a family with primary sclerosing cholangitis. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	1
13	High-dimensional profiling reveals phenotypic heterogeneity and disease-specific alterations of granulocytes in COVID-19. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	14
12	MAIT cell activation and dynamics associated with COVID-19 disease severity. <i>Science Immunology</i> , 2020 , 5,	28	74
11	Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. <i>Cell</i> , 2020 , 183, 158-168.e14	56.2	955
10	Expansion of SARS-CoV-2-Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients. <i>Journal of Immunology</i> , 2020 , 205, 2437-2446	5.3	48
9	Innate lymphoid cell composition associates with COVID-19 disease severity. <i>Clinical and Translational Immunology</i> , 2020 , 9, e1224	6.8	24
8	Serum Markers Associated with Severity and Outcome of Hantavirus Pulmonary Syndrome. <i>Journal of Infectious Diseases</i> , 2019 , 219, 1832-1840	7	19
7	Hantavirus Inhibits TRAIL-Mediated Killing of Infected Cells by Downregulating Death Receptor 5. <i>Cell Reports</i> , 2019 , 28, 2124-2139.e6	10.6	14
6	Human hantavirus infection elicits pronounced redistribution of mononuclear phagocytes in peripheral blood and airways. <i>PLoS Pathogens</i> , 2017 , 13, e1006462	7.6	15
5	Soluble SEMA4D/CD100: A novel immunoregulator in infectious and inflammatory diseases. <i>Clinical Immunology</i> , 2016 , 163, 52-9	9	33
4	Expansion of SARS-CoV-2-specific Antibody-secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients		11
3	MAIT cell activation and dynamics associated with COVID-19 disease severity and outcome		9

2	Shedding of infectious SARS-CoV-2 from airways in hospitalized COVID-19 patients in relation to serum antibody responses	1
1	High-dimensional profiling reveals phenotypic heterogeneity and disease-specific alterations of granulocytes in COVID-19	1